Skip to main content
. 2016 Jun;106(6):1067–1072. doi: 10.2105/AJPH.2016.303090

TABLE 2—

Factors Associated With HCV Seroconversion Among Persons Who Inject Drugs: Vancouver, Canada, 1996–2013

Characteristic HCV Seroconversion,a n = 142, 32.3%, IQR or No. (%) HCV Nonseroconversion, n = 298, 67.7%, IQR or No. (%) Unadjusted RR (95% CI) Adjusted RRb (95% CI)
Uses BZDc 3.44 (2.20, 5.37) 1.67 (1.05, 2.66)
 Yes 67 (47.2) 91 (30.5)
 No 75 (52.8) 207 (69.5)
Median age, by 10-y increments 27.0 (21.5–36.8) 30.9 (23.4–41.2) 0.62 (0.52, 0.74) 0.87 (0.73, 1.03)
Gender 0.69 (0.49, 0.96)
 Male 87 (61.3) 213 (71.5)
 Female 55 (38.7) 85 (28.5)
Race/ethnicity 1.01 (0.73, 1.41)
 White 81 (57.0) 172 (57.7)
 Non-White 61 (43.0) 126 (42.3)
Homelessc 1.67 (1.17, 2.38)
 Yes 73 (51.4) 177 (59.4)
 No 69 (48.6) 121 (40.6)
Engages in methadone maintenancec 0.97 (0.67, 1.42)
 Yes 43 (30.3) 109 (36.6)
 No 99 (69.7) 189 (63.4)
Injects heroin dailyc 3.50 (2.51, 4.87) 1.93 (1.34, 2.79)
 Yes 93 (65.5) 152 (51.0)
 No 49 (34.5) 146 (49.0)
Injects cocaine dailyc 3.97 (2.72, 5.80) 2.27 (1.52, 3.37)
 Yes 64 (45.1) 86 (28.9)
 No 78 (54.9) 212 (71.1)
Uses noninjection crack dailyc 1.07 (0.73, 1.57)
 Yes 60 (42.3) 153 (51.3)
 No 82 (57.7) 145 (48.7)
Engages in unsafe sexc 1.61 (1.14, 2.28)
 Yes 96 (67.6) 188 (63.1)
 No 46 (32.4) 110 (36.9)
Involved in sex workc 3.41 (2.33, 5.00)
 Yes 51 (35.9) 80 (26.8)
 No 91 (64.1) 218 (73.2)
Study cohort 0.42 (0.23, 0.78)
 ACCESS 131 (92.3) 224 (75.2)
 VIDUS 11 (7.7) 74 (24.8)

Note. ACCESS = AIDS Care Cohort to Evaluate Access to Survival Services; BZD = benzodiazepine; CI = confidence interval; IQR = interquartile range; RR = rate ratio; VIDUS = Vancouver Injection Drug Users Study. The sample size was n = 440.

a

Number of individuals ever reporting each characteristic during follow-up.

b

A confounder selection approach was used to select values.

c

Activities or situations occurring in the past 6 months.